Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:29:40 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Q:MNKD - MANNKIND CORPORATION - https://www.mannkindcorp.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MNKD - Q5.05.62·6.813.05.78+0.274.93,012.616,6719,6715.59  5.86  5.5256.51  3.38518:34:38Jan 2615 min RT 2¢

Recent Trades - Last 10 of 9671
Time ETExPriceChangeVolume
18:34:38Q5.75680.2468500
18:07:44Q5.780.27100
18:05:15Q5.780.27100
17:29:08Q5.700.192
17:29:08Q5.770.267
17:09:28Q5.890.3810
16:38:17Q5.700.195
16:11:56Q5.790.283
16:10:04Q5.780.271
16:10:04Q5.780.271

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-26 06:05U:MNKDNews ReleaseMannKind Announces FDA Approval of Updated Afrezza(TM) Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
2026-01-23 12:56U:MNKDNews ReleaseBreaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
2026-01-08 08:05U:MNKDNews ReleaseMannKind Provides Business Updates and 2026 Growth Drivers
2025-12-23 08:05U:MNKDNews ReleaseMannKind Shares FUROSCIX(TM) Business Updates
2025-12-01 08:05U:MNKDNews ReleaseMannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow(TM) Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
2025-11-11 16:05U:MNKDNews ReleaseMannKind to Present at the Jefferies Global Healthcare Conference
2025-11-10 08:00U:MNKDNews ReleaseMannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
2025-11-06 09:00U:MNKDNews ReleaseMannKind Commemorates Alfred E. Mann's 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
2025-11-05 08:00U:MNKDNews ReleaseMannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
2025-10-29 16:05U:MNKDNews ReleaseMannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
2025-10-13 08:05U:MNKDNews ReleaseMannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
2025-10-07 09:02U:MNKDNews ReleaseMannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
2025-09-29 06:05U:MNKDNews ReleaseMannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
2025-08-27 16:05U:MNKDNews ReleaseMannKind to Present at Upcoming Investor Conferences
2025-08-27 08:05U:MNKDNews ReleaseMannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
2025-08-25 07:31U:MNKDNews ReleaseMannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
2025-08-06 07:10U:MNKDNews ReleaseMannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
2025-08-06 07:05U:MNKDNews ReleaseMannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update